Tiziana Doses First Three Patients in Phase 2a ALS BANYAN Trial of Intranasal Foralumab
TLSA sits 31% above its 52-week low of $0.762.
Summary
Tiziana Life Sciences announced the first three participants have been dosed in its Phase 2a Healey ALS MyMatch BANYAN trial of intranasal foralumab, with detailed trial design and multiple U.S. sites disclosed.
Key Events · Product Development and Regulatory · TLSA
-
First Patients Dosed in BANYAN Trial
First three participants received their first dose of intranasal foralumab in the Phase 2a Healey ALS MyMatch BANYAN clinical trial.
-
Trial Design and Endpoints
44 participants with early ALS, 3:1 randomization, 12-week treatment plus 12-week extension; primary endpoint safety/tolerability, secondary endpoints include Tregs, NfL, and TSPO-PET/MRI.
-
Multiple U.S. Trial Sites
Trial conducted at Healey & AMG Center (Boston), Les Turner ALS Center at Northwestern Medicine (Chicago), University of Minnesota (Minneapolis), and Nova Southeastern University (Davie, FL).
-
ALS Association Co-Funding
Study co-funded by the ALS Association through its Hoffman ALS Clinical Trial Awards Program.
Analysis · TLSA · Life Sciences
First patient dosing in the BANYAN trial marks a concrete clinical milestone for Tiziana's lead asset in ALS, a disease with urgent unmet need. The trial is co-funded by the ALS Association and conducted at the Healey & AMG Center, lending credibility. With 44 participants and biomarker-driven endpoints including Tregs, NfL, and TSPO-PET/MRI, this study could generate meaningful data on foralumab's mechanism in ALS. The announcement follows a series of insider purchases by the CEO and Executive Chairman over the past two months, suggesting management confidence in the program.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.9% of the 1656 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TLSA was trading at $1.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $129.6M. The 52-week trading range was $0.76 to $2.35. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.